Skip to content
中文产业新闻评分61Chinese source

伏罗尼布wAMD三期临床失败，EyePoint股价大跌67%，贝达药业持大中华区权益

EyePoint大跌67%：伏罗尼布wAMD三期临床失败，贝达药业拥有大中华区权益

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.